3 transcripts
DVAX
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
initiatives over the next several quarters to effectively implement the recommendation. Over half of our targeted IDM universe has increased hepatitis B dose
DVAX
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
and an overall increase in targeted commercial investments designed to drive HEPLISAV-B market share and maximize the opportunities presented by the ACIP's
DVAX
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
million for the prior period. The increase was primarily driven by higher personnel-related costs and an overall increase in targeted marketing
- Prev
- 1
- Next